Literature DB >> 29424186

Spinal cord injury in endovascular thoracoabdominal aortic aneurysm repair: prevalence, risk factors and preventive strategies.

Vítor Miranda1, Joel Sousa2,3, Armando Mansilha1,3.   

Abstract

Thoracoabdominal aortic aneurysms are among the most challenging pathologic conditions vascular surgeons have to face. Endovascular treatment brought the prospect of being able to treat these complex aneurysms with less invasiveness and recent outcomes already challenge those of open repair. Plus, this technique offers a therapeutic option for patients who had none, due to significant comorbidities limiting open repair. Spinal cord injury is a major complication after complex aneurysm repair that dramatically affects patient's quality of life, even if technical success - aneurysm exclusion from circulation - has been achieved. Several strategies to prevent this terrible outcome have been developed, with remarkable success in narrowing down the number of patients who will suffer this complication. This comprehensive review covers how the standard of care for thoracoabdominal aortic aneurysms has evolved over time, how the understanding of spinal cord perfusion has changed in light of the collateral network concept, the risk factors associated with SCI, and details preventive strategies applied in current practice to lessen even further the frequency of spinal cord injury. Strategies covered go from the traditional adjuncts comprising hemodynamic control, neuroprotective drugs, neuromonitoring and cerebrospinal fluid drainage to emerging and innovative techniques such as near-infrared spectroscopy, two-step repair, minimally-invasive selective segmental artery coil-embolization, temporary aneurysm sac perfusion, and techniques for earlier pelvic and lower limb reperfusion.

Entities:  

Mesh:

Year:  2018        PMID: 29424186     DOI: 10.23736/S0392-9590.18.03960-3

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  7 in total

1.  The Pathway of Let-7a-1/2-3p and HMGB1 Mediated Dexmedetomidine Inhibiting Microglia Activation in Spinal Cord Ischemia-Reperfusion Injury Mice.

Authors:  Ming Nuo; Qing-Tao Meng; Zhong-Yuan Xia
Journal:  J Mol Neurosci       Date:  2019-06-12       Impact factor: 3.444

2.  Cerebrospinal fluid drainage in thoracic endovascular aortic repair: mandatory access but tailored placement.

Authors:  Cenea Kemp; Yuki Ikeno; Muhammad Aftab; T Brett Reece
Journal:  Ann Cardiothorac Surg       Date:  2022-01

3.  Baicalein Attenuates Pyroptosis and Endoplasmic Reticulum Stress Following Spinal Cord Ischemia-Reperfusion Injury via Autophagy Enhancement.

Authors:  Chenyu Wu; Hui Xu; Jiafeng Li; Xinli Hu; Xingyu Wang; Yijia Huang; Yao Li; Sunren Sheng; Yongli Wang; Huazi Xu; Wenfei Ni; Kailiang Zhou
Journal:  Front Pharmacol       Date:  2020-07-30       Impact factor: 5.810

4.  CNB-001 reduces paraplegia in rabbits following spinal cord ischemia.

Authors:  Paul A Lapchak; Paul D Boitano; Rene Bombien; Daisy Chou; Margot Knight; Anja Muehle; Mihaela Te Winkel; Ali Khoynezhad
Journal:  Neural Regen Res       Date:  2019-12       Impact factor: 5.135

5.  Measuring CMAPs in addition to MEPs can distinguish peripheral ischemia from spinal cord ischemia during endovascular aortic repair.

Authors:  Fabian I Kerkhof; Jan van Schaik; Richard A Massaad; Catharina S P van Rijswijk; Martijn R Tannemaat
Journal:  Clin Neurophysiol Pract       Date:  2020-12-11

Review 6.  Effects of Lipoic Acid on Ischemia-Reperfusion Injury.

Authors:  Yueming Ding; Yiming Zhang; Wunong Zhang; Jia Shang; Zhenxing Xie; Chaoran Chen
Journal:  Oxid Med Cell Longev       Date:  2021-10-05       Impact factor: 6.543

7.  Inhibition of heat shock protein family A member 8 attenuates spinal cord ischemia-reperfusion injury via astrocyte NF-κB/NLRP3 inflammasome pathway : HSPA8 inhibition protects spinal ischemia-reperfusion injury.

Authors:  Jingyi Mi; Yang Yang; Hao Yao; Zhirong Huan; Ce Xu; Zhiheng Ren; Wenfu Li; Ying Tang; Rao Fu; Xin Ge
Journal:  J Neuroinflammation       Date:  2021-08-06       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.